Abstract: Disclosed in the present invention is a crystalline form of fluvatinib or fluvatinib methanesulfonate, and a preparation method therefor. The crystalline form I of the fluvatinib has characteristic diffraction peaks as shown in FIG. 1. The crystalline form of the fluvatinib methanesulfonate may take multiple forms, including seven crystalline forms, forms I-VII, wherein crystalline form III has characteristic diffraction peaks as shown in FIG. 9. Said crystalline forms are suited to manufacturing processes for fluvatinib methanesulfonate formulations.

Abstract: The present invention relates to the field of pharmaceutical chemistry, and particularly to a crystal form of Abiraterone propionate and a preparation method therefor. Characteristic diffraction peaks occur at positions, where the 2? value is 5.7°, 11.9°, 12.4°, 14.9°, 15.8°, 16.7°, 18.5°, 19.1°, 21.7°, 22.4°, and 39.9°±0.2°, in an X-ray powder diffraction spectrum of the crystal form of Abiraterone propionate.

Abstract: The present invention relates to the field of pharmaceutical chemistry, and particularly to a crystal form of Abiraterone propionate and a preparation method therefor. Characteristic diffraction peaks occur at positions, where the 2? value is 5.7°, 11.9°, 12.4°, 14.9°, 15.8°, 16.7°, 18.5°, 19.1°, 21.7°, 22.4°, and 39.9°±0.2°, in an X-ray powder diffraction spectrum of the crystal form of Abiraterone propionate.

Abstract: The present invention provides a stable composition of rasagiline comprising an effective dosage of rasagiline or its pharmaceutically acceptable salts and an antioxidant used as a stabilizer. The dosage forms of the composition are pharmaceutically common transdermal-drug delivery dosage form and mucoadhesive delivery dosage form, such as patch, gel, ointment, cream, cataplasm, film, spray and solution, etc. The composition can be used to prevent or treat mental disorders.

Abstract: A method of purifying a salt of pemetrexed having a structure of formula (III) by salting-out, wherein if M3+ is H+, then each of M1+ and M2+ is independently H+, Li+, Na+ or K+, provided that both of them are not H+; if M3+ is Li+, Na+ or K+, then each of M1+ and M2+ is independently Li+, Na+ or K+.

Abstract: The present invention relates to morphinan derivatives and preparation methods thereof, especially to ketal hydroxyl protected compounds of morphinan derivatives and preparation method thereof, and to a method for preparing corresponding alkylated morphinan derivatives by using the ketal hydroxyl protected compounds as intermediates, and more especially to a ketal hydroxyl protected compound of methylnaltrexone as intermediate for preparing methylnaltrexone and a method for preparing methylnaltrexone through said intermediate.

Abstract: Three new crystalline forms of pemetrexed diacid, preparation methods and uses thereof are disclosed. These preparation processes are simple and have better practicality.

Abstract: The present invention provides a stable composition of rasagiline comprising an effective dosage of rasagiline or its pharmaceutically acceptable salts and an antioxidant used as a stabilizer. The dosage forms of the composition are pharmaceutically common transdermal-drug delivery dosage form and mucoadhesive delivery dosage form, such as patch, gel, ointment, cream, cataplasm, film, spray and solution, etc. The composition can be used to prevent or treat mental disorders.

Abstract: A febuxostat which purity is not less than 99.0%, method for preparation thereof, and pharmaceutical composition thereof. The method for preparation includes recrystallizing febuxostat in a mixed solvent. The said pharmaceutical composition can be used in manufacture of medicaments for treating diseases associated with hyperuricemia.

Abstract: The invention discloses a process for preparing a polynuclear ferric hydroxide-saccharide complex, including: adding an aqueous solution of an alkaline substance drop-wise into an aqueous solution of iron salt at a temperature of 5-20° C. until pH 6-8, collecting the polynuclear ferric hydroxide from the reaction mixture by a conventional method; reacting the polynuclear ferric hydroxide with a saccharide in a solution of an alkaline substance for 10-40 hours at 106-125° C. under pH 10-12, resulting in a crude product having an isoelectric point of 4.4-5.3 and a weight average molecular weight of 20,000-100,000 Daltons, and then harvesting the polynuclear ferric hydroxide-saccharide complex from the crude product. The process can precisely control the molecular weight of the polynuclear ferric hydroxide-saccharide complex without an effect on the other characteristics of the product, for example its saccharide content or isoelectric point etc. Furthermore, it is very simple and readily applicable in industry.

Abstract: Three new crystalline forms of pemetrexed diacid, preparation methods and uses thereof are disclosed. These preparation processes are simple and have better practicality.

Abstract: The present invention relates to morphinan derivatives and preparation methods thereof, especially to ketal hydroxyl protected compounds of morphinan derivatives and preparation method thereof, and to a method for preparing corresponding alkylated morphinan derivatives by using the ketal hydroxyl protected compounds as intermediates, and more especially to a ketal hydroxyl protected compound of methylnaltrexone as intermediate for preparing methylnaltrexone and a method for preparing methylnaltrexone through said intermediate.

Abstract: The present invention relates to a rasagiline transdermal patch for treatment or prophylaxis of nervous system diseases, in which the patch comprises an inert backing layer chemically inert to substrate ingredients, a substrate layer comprising rasagiline or a pharmaceutically acceptable salt thereof, and a protective layer to be peeled off before use. The substrate layer is an adhesive system comprising an organic polymer material as basis and an inorganic or organic material as filler, and a plurality of micro-reservoirs containing rasagiline. The substrate further comprises one or more substances for enhancing the transdermal absorption of rasagiline, in which the above organic polymer material in the substrate is used for the reservoir of rasagiline and as adhesive.

Abstract: The invention discloses a process for preparing a polynuclear ferric hydroxide-saccharide complex, including: adding an aqueous solution of an alkaline substance drop-wise into an aqueous solution of iron salt at a temperature of 5-20° C. until pH 6-8, collecting the polynuclear ferric hydroxide from the reaction mixture by a conventional method; reacting the polynuclear ferric hydroxide with a saccharide in a solution of an alkaline substance for 10-40 hours at 106-125° C. under pH 10-12, resulting in a crude product having an isoelectric point of 4.4-5.3 and a weight average molecular weight of 20,000-100,000 Daltons, and then harvesting the polynuclear ferric hydroxide-saccharide complex from the crude product. The process can precisely control the molecular weight of the polynuclear ferric hydroxide-saccharide complex without an effect on the other characteristics of the product, for example its saccharide content or isoelectric point etc. Furthermore, it is very simple and readily applicable in industry.